$95.06
Revenue is up for the last 2 quarters, 33.58K → 47.39M (in $), with an average increase of 99.9% per quarter
Netprofit is up for the last 2 quarters, -207.41M → -121.43M (in $), with an average increase of 70.8% per quarter
In the last 1 year, Novo Nordisk A/s has given 288.9% return, outperforming this stock by 294.5%
In the last 3 years, Novo Nordisk A/s has given 451.5% return, outperforming this stock by 489.8%
0.5%
Downside
Day's Volatility :2.56%
Upside
2.07%
32.33%
Downside
52 Weeks Volatility :52.18%
Upside
29.34%
Period | Ascendis Pharma A/s | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 9.77% | -1.4% | 0.0% |
6 Months | -12.44% | 2.2% | 2.0% |
1 Year | -3.64% | 6.0% | 5.3% |
3 Years | -38.28% | 26.3% | 19.9% |
Market Capitalization | 5.4B |
Book Value | $1.15 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -10.84 |
Wall Street Target Price | 0.34 |
Profit Margin | 0.0% |
Operating Margin TTM | -483.7% |
Return On Assets TTM | -33.5% |
Return On Equity TTM | -180.98% |
Revenue TTM | 119.2M |
Revenue Per Share TTM | 2.13 |
Quarterly Revenue Growth YOY | 669.4% |
Gross Profit TTM | 39.0M |
EBITDA | -570.3M |
Diluted Eps TTM | -10.84 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.04 |
EPS Estimate Next Year | -0.01 |
EPS Estimate Current Quarter | -2.74 |
EPS Estimate Next Quarter | -2.69 |
What analysts predicted
Downside of 99.64%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 1.5M | ↓ 66.78% |
Net Income | -123.9M | ↑ 80.86% |
Net Profit Margin | -8.1K% | ↓ 6610.54% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 10.6M | ↑ 591.57% |
Net Income | -130.1M | ↑ 5.0% |
Net Profit Margin | -1.2K% | ↑ 6868.31% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 13.4M | ↑ 26.41% |
Net Income | -218.0M | ↑ 67.58% |
Net Profit Margin | -1.6K% | ↓ 400.5% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 7.0M | ↓ 48.01% |
Net Income | -419.0M | ↑ 92.17% |
Net Profit Margin | -6.0K% | ↓ 4395.5% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 8.8M | ↑ 11.87% |
Net Income | -434.4M | ↓ 8.44% |
Net Profit Margin | -4.9K% | ↑ 1093.97% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 54.8M | ↑ 557.93% |
Net Income | -624.7M | ↑ 52.04% |
Net Profit Margin | -1.1K% | ↑ 3791.93% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 7.6M | ↑ 39.4% |
Net Income | -140.1M | ↑ 18.32% |
Net Profit Margin | -1.8K% | ↑ 327.44% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 6.4M | ↓ 9.78% |
Net Income | -85.0M | ↓ 35.2% |
Net Profit Margin | -1.3K% | ↑ 517.88% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 15.0M | ↑ 148.21% |
Net Income | -166.1M | ↑ 107.77% |
Net Profit Margin | -1.1K% | ↑ 215.11% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 24.5M | ↑ 49.74% |
Net Income | -222.2M | ↑ 22.77% |
Net Profit Margin | -905.91% | ↑ 199.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 51.7M | ↑ 140996.79% |
Net Income | -132.5M | - |
Net Profit Margin | -256.23% | - |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 211.0M | ↑ 11.0% |
Total Liabilities | 23.8M | ↑ 76.61% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 319.0M | ↑ 51.18% |
Total Liabilities | 38.9M | ↑ 63.74% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 676.7M | ↑ 112.16% |
Total Liabilities | 79.6M | ↑ 104.58% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 979.8M | ↑ 44.78% |
Total Liabilities | 141.1M | ↑ 77.2% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↑ 10.73% |
Total Liabilities | 228.0M | ↑ 42.67% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↑ 0.44% |
Total Liabilities | 885.3M | ↑ 310.56% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↑ 26.94% |
Total Liabilities | 786.3M | ↑ 249.97% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↓ 3.66% |
Total Liabilities | 751.1M | ↑ 2.07% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 4.03% |
Total Liabilities | 807.9M | ↑ 14.31% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 14.42% |
Total Liabilities | 885.3M | ↑ 0.55% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↓ 11.33% |
Total Liabilities | 871.4M | ↓ 3.31% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 898.9M | ↓ 14.74% |
Total Liabilities | 828.1M | ↓ 5.02% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -95.1M | ↑ 58.03% |
Investing Cash Flow | -941.0K | ↑ 40.03% |
Financing Cash Flow | 124.7M | ↑ 6.18% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -138.8M | ↑ 45.96% |
Investing Cash Flow | -2.6M | ↑ 181.4% |
Financing Cash Flow | 203.3M | ↑ 62.98% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -175.9M | ↑ 26.75% |
Investing Cash Flow | -5.2M | ↑ 94.83% |
Financing Cash Flow | 493.6M | ↑ 142.83% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -271.5M | ↑ 54.34% |
Investing Cash Flow | -291.2M | ↑ 5544.49% |
Financing Cash Flow | 602.7M | ↑ 22.09% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -473.0M | ↑ 53.8% |
Investing Cash Flow | -125.2M | ↓ 62.03% |
Financing Cash Flow | 397.9M | ↓ 41.69% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -146.0M | ↑ 6.06% |
Investing Cash Flow | 43.0M | ↓ 134.44% |
Financing Cash Flow | 444.0M | ↓ 2028.04% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -130.0M | ↓ 4.89% |
Investing Cash Flow | 10.3M | ↓ 74.34% |
Financing Cash Flow | -2.3M | ↓ 100.56% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -97.2M | ↓ 20.55% |
Investing Cash Flow | 13.9M | ↑ 42.59% |
Financing Cash Flow | -74.7K | ↓ 96.6% |
Sell
Neutral
Buy
Ascendis Pharma A/s is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Ascendis Pharma A/s | -3.89% | -12.44% | -3.64% | -38.28% | 42.28% |
![]() Moderna, Inc. | -10.67% | -32.6% | -16.46% | 43.93% | 437.58% |
![]() Regeneron Pharmaceuticals, Inc. | -0.66% | 0.54% | 20.22% | 43.69% | 111.47% |
![]() Novo Nordisk A/s | 2.15% | 146.19% | 299.73% | 451.49% | 690.33% |
![]() Seagen, Inc. | 6.95% | 7.06% | 57.98% | 15.54% | 167.56% |
![]() Vertex Pharmaceuticals Incorporated | -0.15% | 13.31% | 26.28% | 30.33% | 91.37% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Ascendis Pharma A/s | NA | NA | NA | -0.04 | -1.81 | -0.33 | 0.0 | 1.15 |
![]() Moderna, Inc. | 34.92 | 34.92 | 0.0 | -3.42 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 21.9 | 21.9 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 42.86 | 42.86 | 2.03 | 1.66 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 27.48 | 27.48 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Ascendis Pharma A/s | Buy | $5.4B | 42.28% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $38.1B | 437.58% | 34.92 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $89.4B | 111.47% | 21.9 | 33.93% |
![]() Novo Nordisk A/s | Buy | $409.3B | 690.33% | 42.86 | 33.4% |
![]() Seagen, Inc. | Hold | $38.7B | 167.56% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.2B | 91.37% | 27.48 | 35.4% |
RA Capital Management, LLC
Artisan Partners Limited Partnership
FMR Inc
T. Rowe Price Investment Management,Inc.
HHG PLC
Westfield Capital Management Company, LP
Ascendis Pharma A/s’s price-to-earnings ratio stands at None
Read Moreascendis pharma a/s is a biotechnology company located in 12 tuborg blvd., hellerup, capital region of denmark, denmark.
Organization | Ascendis Pharma A/s |
Employees | 797 |
CEO | Mr. Jan Moller Mikkelsen |
Industry | Health Technology |